The independent medical news service

Breast, prostate, and colorectal cancer screening rates declined sharply during the initial months of the COVID-19 pandemic in the USA, and while they subsequently recovered, a large deficit remains, study findings indicate.

Men with metastatic castration-sensitive prostate cancer continue to derive a survival benefit from the addition of apalutamide to androgen deprivation therapy, suggest long-term data from the TITAN trial.

The American Heart Association has released a consensus statement on the management of cardiovascular disease in patients receiving hormonal therapies for breast or prostate cancer.

An analysis of the FDA Adverse Event Reporting System has provided detailed insight into cardiovascular adverse events associated with different classes of androgen deprivation therapies.

An extensive meta-analysis of individual participant data has not found consistent evidence to indicate that antihypertensive use is associated with an increased risk for cancer.

Men with a high genetic risk for developing prostate cancer may be able to offset the risk for lethal disease by maintaining a healthy lifestyle, findings indicate.